このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

3SBio 過去の業績

過去基準チェック /26

3SBioは、平均年間13%の収益成長を遂げていますが、 Biotechs業界の収益は、年間成長しています。収益は、平均年間11.7% 10%収益成長率で成長しています。 3SBioの自己資本利益率は9.6%であり、純利益率は19.8%です。

主要情報

13.0%

収益成長率

14.0%

EPS成長率

Biotechs 業界の成長	11.0%
収益成長率	10.0%
株主資本利益率	9.6%
ネット・マージン	19.8%
前回の決算情報	31 Dec 2023

Recent updates

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

収支内訳

3SBio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:1530 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	7,816	1,549	3,487	795
30 Sep 23	7,686	1,739	3,351	750
30 Jun 23	7,549	1,929	3,205	705
31 Mar 23	7,204	1,922	3,085	699
31 Dec 22	6,866	1,916	2,974	694
30 Sep 22	6,618	1,817	2,849	699
30 Jun 22	6,369	1,719	2,725	703
31 Mar 22	6,376	1,685	2,710	729
31 Dec 21	6,382	1,651	2,696	754
30 Sep 21	6,191	1,342	2,688	717
30 Jun 21	6,000	1,032	2,681	681
31 Mar 21	5,794	934	2,577	636
31 Dec 20	5,588	836	2,472	590
30 Sep 20	5,479	1,095	2,535	581
30 Jun 20	5,370	1,355	2,598	571
31 Mar 20	5,344	1,164	2,612	549
31 Dec 19	5,318	974	2,627	527
30 Sep 19	5,185	1,029	2,409	549
30 Jun 19	5,053	1,084	2,190	572
31 Mar 19	4,818	1,181	2,099	468
31 Dec 18	4,584	1,277	2,008	363
30 Sep 18	4,393	1,167	1,911	181
30 Jun 18	4,202	1,057	1,814	0
31 Mar 18	3,968	996	1,731	0
31 Dec 17	3,734	935	1,648	0
30 Sep 17	3,467	877	1,601	0
30 Jun 17	3,199	818	1,555	0
31 Mar 17	2,998	766	1,437	0
31 Dec 16	2,797	713	1,318	0
30 Sep 16	2,492	642	1,104	0
30 Jun 16	2,188	571	889	0
31 Mar 16	1,930	548	800	0
31 Dec 15	1,673	526	710	0
30 Sep 15	1,503	456	676	0
30 Jun 15	1,364	341	744	0
31 Mar 15	1,247	316	673	0
31 Dec 14	1,131	292	602	0
30 Sep 14	1,044	238	581	0
31 Dec 13	875	96	439	0
30 Sep 13	842	95	432	-54

質の高い収益: 1530は高品質の収益を持っています。

利益率の向上: 1530の現在の純利益率 (19.8%)は、昨年(27.9%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 1530の収益は過去 5 年間で年間13%増加しました。

成長の加速: 1530は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: 1530は過去 1 年間で収益成長率がマイナス ( -19.1% ) となったため、 Biotechs業界平均 ( 22.1% ) と比較することが困難です。

株主資本利益率

高いROE: 1530の自己資本利益率 ( 9.6% ) は低いとみなされます。

3SBio 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

First half 2023 earnings: EPS and revenues exceed analyst expectations

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Consensus EPS estimates fall to CN¥0.52

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

過去基準チェック /26